IDH1 and astrocytoma (excluding glioblastoma): This difference in median survival between non-TCGA and TCGA cohorts was more pronounced for IDH1/2-mutant astrocytoma, where non-TCGA patients had a median survival of 136.8 months (range: 1.0–262.2 months), compared to 87.9 months (range: 0.1–157.1 months, P = .0002) in TCGA patients (Figure 4C).